Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2 ‐year Clinical Trial

ABSTRACTCessation of denosumab treatment is associated with increases in bone turnover above baseline values and rapid bone loss. We investigated the efficacy of zoledronate to prevent this bone loss in women with postmenopausal osteoporosis who were treated with denosumab (mean duration 2.2  years) and discontinued treatment after achieving osteopenia. Women were randomized to receive a single zoledronate 5 mg infusion (n = 27) or two additional denosumab 60 mg injections (n = 30). Both groups were followed for a total period of 24 months. At 24 months LS‐BMD was not di fferent from baseline in the ZOL group, but decreased in the Dmab group by 4.82 ± 0.7% (p 
Source: Journal of Bone and Mineral Research - Category: Orthopaedics Authors: Tags: Original Article Source Type: research

Related Links:

In conclusion, reducing miR-451a expression levels could enhance bone formation during the progression of osteoporosis, which might be at least partly via the meditation of Bmp6 expression.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Source: Clinical Interventions in Aging - Category: Geriatrics Tags: Clinical Interventions in Aging Source Type: research
Conclusion: Several health maintenance aspects are inadequately addressed by GIs and PCPs, in part because of conflicting perceptions of responsibility. Clear guidelines and better GI/PCP communication are required to ensure effective health maintenance for patients with IBD. PMID: 31528131 [PubMed]
Source: Ochsner Journal - Category: General Medicine Tags: Ochsner J Source Type: research
In conclusion, we found osteoblastogenesis was reduced in an acidic environment, and ASIC2, ASIC3, and ASIC4 were most highly expressed in turn during osteoblastogenesis within acidic media. ASIC2 was the most abundantly expressed gene in human bone cells in OVF compared with the control. ASIC2 could be crucial in the pathogenesis of osteoporosis and could serve as a therapeutic target for antiosteoporotic therapies. PMID: 31531354 [PubMed - in process]
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
A new ultrasound technique could help clinicians assess bone health and distinguish...Read more on AuntMinnie.comRelated Reading: AAOS: QCT finds low bone density in lumbar fusion patients 3D DEXA enhances hip fracture risk prediction Ultrasound equal to DEXA for assessing bone health USPSTF reaffirms osteoporosis screening USPSTF to review osteoporosis screening
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Setting aside the mice genetically engineered to destroy senescent cells, the combination of dasatinib and quercetin is the oldest of the senolytic treatments used in animal studies. Senolytic therapies are those that selectively destroy senescent cells in old tissues in order to produce rejuvenation, turning back the progression of numerous age-related conditions. Unusually for early stage research, these initial senolytics are actually quite effective, considered in the grand scheme of things. Thus they have moved directly to human trials in some cases. The first data on their ability to produce the same outcomes in huma...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
Publication date: Available online 17 September 2019Source: Enzyme and Microbial TechnologyAuthor(s): Yuping Shen, Man Wang, Jinwei Zhou, Yufei Chen, Lili Xu, Mengru Wu, Guohua Xia, James P. Tam, Jiangnan Yu, Xiying Teng, Huan Yang, Xiaobin JiaABSTRACTBaohuoside I, a rare secondary glycoside from Epimedii Folium, has anti-osteoporosis and other pharmacological effects. In addition, it exhibits improved bioactivities compared with its original glycoside icariin. Conventional methods for the production of baohuoside I, such as acid hydrolysis, exhibit very low efficiency with serious pollution and substantial byproducts. The...
Source: Enzyme and Microbial Technology - Category: Biotechnology Source Type: research
Conditions:   Diabetes Mellitus;   Diabetes Mellitus, Type 2;   Obesity;   Body Weight;   Bone Diseases, Metabolic;   Fractures, Bone;   Osteoporotic Fractures;   Osteoporosis;   Quality of Life;   Fall;   Musculoskeletal Diseases Intervention:   Sponsors:   Suzanne Morin;   CHU de Quebec-Universite Laval Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Study Design. Prospective research in middle-aged and elderly people. Objective. To investigate low back pain (LBP) and neuropathic pain (NeP); spinal alignment and range of motion (ROM); spinal degenerative changes in plain radiography; osteoporosis; muscle strength; and physical ability as possible risk factors for poor quality of life (QOL). Summary of Background Data. The aging of society has led to an increase in elderly people with chronic pain, including LBP and NeP. However, there has been no analysis of NeP and spinal sagittal alignment as potential risk factors for decreased QOL in the healthy general pop...
Source: Spine - Category: Orthopaedics Tags: CLINICAL CASE SERIES Source Type: research
The objective of the present study was to compare the long-term incidence of reoperation for lumbar herniated intervertebral disc disease (HIVD) after major surgical techniques (open discectomy, OD; laminectomy; percutaneous endoscopic lumbar discectomy, PELD; fusion). Summary of Background Data. HIVD is a major spinal affliction; if the disease is intractable, surgery is recommended. Considering both the aging of patients and the chronicity of lumbar degenerative disease, the effect of surgical treatment for the lumbar spine should be durable for as long as possible. Methods. The National Health Insurance Service-Na...
Source: Spine - Category: Orthopaedics Tags: HEALTH SERVICES RESEARCH Source Type: research
More News: Clinical Trials | Orthopaedics | Osteoporosis | Statistics | Study | Women | Xgeva